Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Australian PE snubbed twice in a day as firms seek higher offers

Published 2018-11-12, 03:44 a/m
Updated 2018-11-12, 03:44 a/m
© Reuters.  Australian PE snubbed twice in a day as firms seek higher offers

© Reuters. Australian PE snubbed twice in a day as firms seek higher offers

* Healthscope and Navitas spurn offers from BGH Capital

* BGH offered combined $6.1 billion for the two firms

* Healthscope picks higher offer from Brookfield

* Navitas says in talks with others

By Byron Kaye and Paulina Duran

SYDNEY, Nov 12 (Reuters) - BGH Capital, an Australian private-equity firm run by three star deal-makers, was rebuffed on two billion-dollar deals on Monday, underscoring how companies are trying to squeeze out better offers in a market crammed with cash-rich investors.

Earlier in the day, Healthscope Ltd HSO.AX said it had picked Brookfield Capital Partners' sweetened offer that values the hospital operator at up to A$4.5 billion ($3.24 billion) over BGH's A$4.1 billion bid. Ltd NVT.AX also snubbed BGH, saying its A$1.97 billion bid undervalued the adult education provider, but kept the door ajar for a future deal or a rival bidder. rejections crush what BGH had hoped would be its first purchases since it was set up last year by former local heads of U.S. private-equity giant TPG Capital Management LP TPG.UL and Australia's Macquarie Group Ltd MQG.AX .

"What we are witnessing is a huge amount of interest from private capital in investment opportunities," a managing director of a top investment bank said on condition of anonymity. "There's been a lot of money raised and people are very keen to put that money to work."

Australia's private-equity industry has raised A$5.4 billion in 2018, the most in a decade, according to the Australian Private Equity & Venture Capital Association Ltd.

This has spurred brisk deal-making as interest rates have stayed low in the region, with funds looking to buy Australian firms such as Sirtex Medical, Colonial First State Global Asset Management and Murray Goulburn in the health, finance and agriculture industries at hefty multiples.

Brookfield's $2.585 per share offer for Healthscope is 24 percent above the firm's Friday stock close, while BGH's spurned bid for Navitas was at a 26 percent premium to an Oct. 9 close.

Melbourne-based Healthscope's profits have been falling as the number of Australians taking out private health cover has stalled. But the company's large hospital property portfolio has made it an attractive target for suitors looking at Australia's ageing population as a source of long-term growth.

Healthscope shares jumped 14.4 percent on Monday, in a broader market that was up 0.3 percent.

Navitas shares were steady. The company has seen enrolments drop in North America, a major market, amid an immigration crackdown led by U.S. President Donald Trump.

PRUDENT DEALMAKING

Healthscope, which had in May snubbed offers from Brookfield and BGH, said Brookfield's new offer was superior and it would grant Brookfield exclusive access to due diligence to facilitate a binding offer. drop in Healthscope shares, down 11 percent since end-May, is likely to have changed its mind about engaging with Brookfield, Morningstar analyst Gareth James said.

Some industry players said BGH could be making a prudent choice by not sweetening its offer.

"The last thing they want to do is increase the price to the level where their clients and investors can't make a return on their investment capital," said Simon Mawhinney, chief financial officer at Allan Gray Australia that owns Navitas shares.

"It's an incredibly disciplined approach."

BGH, named after ex-Macquarie banker Robin Bishop, and Ben Gray and Simon Harle - who used to lead the Australian team at TPG Capital Management, was not available for comment. ($1 = 1.3868 Australian dollars)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.